Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The Investor Relations website contains information about Albireo's business for stockholders, potential investors, and financial analysts. Medical Information (857) 378-2035 medinfo@albireopharma.com Company Profile. Albireo Pharma, Inc. | 5,339 followers on LinkedIn. Change Volume 52 Week High 52 Week Low Dec 19, 2020 9:08 AM EST. Source: Albireo Pharma, Inc. Albireo Pharma, Inc. Condensed Consolidated Balance Sheets Albireo Reports Fourth Quarter and Year-End 2019 Financial Results, and Provides Business Update . Profile. Listen to webcast. Revenues came in … 2020© SALVATORE FERRAGAMO S.P.A. - P.IVA: 02175200480 Seguici su Wechat. Albireo Pharma, Inc. is an equal opportunity employer and does not discriminate against any applicant because of race, creed, color, age, national origin, ancestry, religion, gender, sexual orientation, disability, genetic information, veteran status, military status, application for military service or any other class protected by state or federal law. Equal Opportunity Employer. S . Home / Investors & Media / News Releases News Releases. Legacy Housing Corporation is the fourth largest producer of manufactured homes in the United States and a recognized leader and innovator in the manufactured housing industry. Investor Relations Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening … Contatti Investor Relations. The Investor Relations website contains information about Tripadvisor's business for stockholders, potential investors, and financial analysts. Investor Relations Data Provided by Refinitiv. The Investor Relations website contains information about Aeglea Biotherapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. Data Provided by Refinitiv. Investor Relations Global Contacts Albireo Pharma Inc ALBO Morningstar Rating Rating as of Oct 15, 2020. Investor Relations Investor Relations Allakos is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. La Società, la storia, i membri. Operazioni di Cartolarizzazione. Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Corporate Development & Investor Relations Charlotte, NC, USA Phone: 980-299-5601 Mark de Boer Director Corporate Strategy & Investor Relations Amsterdam, The Netherlands Phone: 31 20 634 7060. Shop and Learn. In questa sezione sono pubblicati i documenti relativi a bilanci, III pilastro, rating, operazioni di cartolarizzazione. Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Jan Mattsson, Ph.D. Chief Scientific Officer, Managing Director (Sweden), and Co-Founder Mac; iPad; iPhone; Watch; TV; Music; iTunes; HomePod Explore SAP Investor Relations, with financial news, investor events, annual reports and quarterly statements IREN è stata inclusa per la prima volta dal CDP nella "Climate Change A List" Il Gruppo è stato inserito tra le 8 aziende italiane virtuose nella lotta al cambiamento climatico: il comunicato stampa completo 6 mo. Albireo Launches Expanded Access Program for Odevixibat for Patients in the U.S., Canada, Australia and Europe. A live audio webcast will be accessible from the Media & Investors page of Albireo… The Investor Relations website contains information about Albireo's business for stockholders, potential investors, and financial analysts. Nov 18, 2020 at 1:10 PM EST Jefferies Virtual London Healthcare Conference. The following slide deck was published by Albireo Pharma, Inc. in conjunction with this event. Investor Relations Global Contacts Albireo Pharma Inc ALBO Morningstar Rating Rating as of Nov 17, 2020. The Investor Relations website contains information about Laredo Petroleum, Inc.'s business for stockholders, potential investors, and financial analysts. The Investor Relations website contains information about Legacy Housing Corporation's business for stockholders, potential investors, and financial analysts. Meet the Albireo Pharma enterprise team. Albireo Pharma (ALBO) Investor Presentation - Slideshow. Contact |  Terms of Use  |  Privacy Policy. Albireo has a team of diverse specialists who are determined to improve the lives of people living with a wide range of liver diseases. Tripadvisor, the world's largest travel platform*, helps 463 million travelers each month** make every trip their best trip. III Pilastro. YRC Worldwide Inc., a Fortune 500 company and one of the largest transportation service providers in the world, is the holding company for a portfolio of successful brands, including Holland, New Penn, Reddaway and YRC Freight.YRC Worldwide has the largest, most-comprehensive network in North America with local, regional and national capabilities. Investor Contact: Hans Vitzthum LifeSci Advisors, LLC 212-915-2568. Albireo to Participate in Jefferies and Piper Sandler Virtual Investor Conferences Nov 12, 2020 Albireo Reports Q3 2020 Financial Results and Provides Business Update Minimum 15 minutes delayed. December 10, 2020 Apellis and Sobi Report Positive Top-line Results at 48 Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan in PNH. The Investor Relations website contains information about Albireo's business for stockholders, potential investors, and financial analysts. Albireo Energy has developed a world-class operating team of leaders with wide experience in the building automation, energy efficiency, fire and security contracting business. ET — Download PDF. Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Meet the Albireo Pharma Board of Directors. Thank you, operator, and good morning, everyone. Investors MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. Albireo Pharma, Inc. (ALBO) Q3 2019 Earnings Call Transcript ALBO earnings call for the period ending September 30, 2019. The Investor Relations website contains information about Bentley Systems, Incorporated's business for stockholders, potential investors, and financial analysts. David Chiswell, Ph.D. – Chairman Former CEO, Cambridge Antibody Technology (CAT), Nabriva Therapeutics and Kymab; Currently Chairman, Epsilogen and Board Member of Avillion Bond 2 Development 2 GP and EU primary and secondary endpoints with high ly   statistically significant reductions in serum bile acids and pruritus   - - Interim results from long-term extension study   show sustained improvements in serum bile acids, pruritus - - Improvements in growth, BOSTON , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper , President and Chief Executive Officer, will present via webcast at the 2020 Jefferies London, -   P ositive P hase 3 d ata for   o devixibat in PFIC with filings on track for no later than early 202 1 - -   Phase 3 PFIC data accepted as late breakers at upcoming AASLD Meeting - - Introduces new and novel bile acid modulator A3907 at AASLD - -   Raised $160 million in gross proceeds in. Investor Relations. Thank you for joining today's call during which management will provide an update on Albireo… Thank you for joining today's call. Investor Relations Global Contacts GlobeNewswire Albireo Prices Public Offering of 4,000,000 Shares of Common Stock ... Sep 10, 2020 1:16 AM UTC. E-mail: invest@albemarle.com Paul J. Arndt-- Investor Relations Thank you, operator, and good morning, everyone. Quarterly Earnings Reports. ET — Bilanci. Contact |  Terms of Use  |  Privacy Policy, Progressive Familial Intrahepatic Cholestasis (PFIC), Albireo Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome, Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), Piper Sandler 32nd Annual Healthcare Conference, Albireo Provides Third Quarter 2020 Business Update. 3 mo. Albireo Energy has developed a world-class operating team of leaders with wide experience in the building automation, energy efficiency, fire and security contracting business. Albireo B, di magnitudine 5,1 è invece una stella di classe B8 di sequenza principale, quindi di colore bianco-azzurro, avente una temperatura superficiale di 12.100 kelvin, molto più elevata di quella solare; la sua massa è calcolata essere 3,3 volte quella solare.La sua luminosità è 190 volte quella solare. Investor Relations Investor Relations Corporate Profile. Minimum 15 minutes delayed. Albireo Pharma, Inc. 10 Post Office Square Suite 1000 Boston, MA 02109. 1 yr. Corporate Profile. The Investor Relations website contains information about Albireo's business for stockholders, potential investors, and financial analysts. This page shows the institutions and funds most likely to invest in ALBO / Albireo Pharma, Inc., based on analysis of their current holdings. Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. March 2, 2020 — Phase 3 odevixibat PFIC trial fully enrolled — — Initiating pivotal trials in biliary atresia first half of 2020 and Alagille syndrome by year end— — Management to host conference call and webcast today at 10:00 a.m. Investor Relations Corporate Profile. Find the latest SEC Filings data for Albireo Pharma, Inc. Common Stock (ALBO) at Nasdaq.com. Albireo Pharma, Inc. ... Paul Arndt-- Investor Relations, LifeSci Advisors. Investor Relations Today; 3 mo. Albireo disclaims any obligation to update any forward-looking statement, except as required by applicable law. Investor Relations Overview. Investor Relations Events. Seguici su Snapchat Investor Relations Tripadvisor is the world's largest travel site. Investor Relations Global Contacts ... -8263 (international), and provide the access code 13697430. Allena is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The Investor Relations website contains information about Addus HomeCare's business for stockholders, potential investors, and financial analysts. March 2, 2020 — Phase 3 odevixibat PFIC trial fully enrolled — — Initiating pivotal trials in biliary atresia first half of 2020 and Alagille syndrome by year end— — Management to host conference call and webcast today at 10:00 a.m. CYBEROO nasce nel 2008 all’interno di un retaggio aziendale più ampio, consolidando l’odierno business nel 2019. Albireo, a biotechnology company, develops therapeutic drugs for gastrointestinal diseases. 1 yr. Data Provided by Refinitiv. Find out more. News Releases. VIEW ALL STOCK INFORMATION. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. Albireo Pharma, Inc. Common Stock (ALBO) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Investor Relations Global Contacts Albireo Pharma Inc ALBO Morningstar Rating Rating as of Nov 17, 2020. read more. Avanos Medical is a medical technology company focused on delivering clinically superior breakthrough medical device … Led by a management team with significant experience in … Investor Relations Founded in 2006 by Langley Steinert, co-founder of TripAdvisor, CarGurus is a global, online automotive marketplace connecting buyers and sellers of new and used cars. Albireo Reports Fourth Quarter and Year-End 2019 Financial Results, and Provides Business Update . The Investor Relations website contains information about Albireo's business for stockholders, potential investors, and financial analysts. Phone: (857) 254-5555. Albireo Launches Expanded Access Program for Odevixibat for Patients in the U.S., Canada, Australia and Europe. Paul J. Arndt-- Investor Relations Thank you, operator, and good morning, everyone. - Study represents Albireo’s third global, Phase 3 trial in rare cholestatic liver diseases -              - ASSERT gold standard study design in Alagille syndrome -   - Product submission of once-daily odevixibat for patients with PFIC under review by FDA and EMA - BOSTON , Dec. BOSTON , Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common, - Data   on PFIC types 1, 2, 3 submitted to support use across a wide range of patients - - EMA grants accelerated assessment , validates Marketing Authorization Application for odevixibat with o rphan d esignation and access to PRIority MEdicines (PRIME) - -   FDA has granted o devixibat   F ast T, - PEDFIC 1   meets   both U . Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in … The Investor Relations website contains information about Safilo Group S.p.A.'s business for stockholders, potential investors, and financial analysts. Investor Relations. Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Media Contact: Heather Anderson 6 Degrees 980-938-0260 handerson@6degreespr.com. ABOUT ALDEYRA. Per la trasmissione e lo stoccaggio delle Informazioni Regolamentate, la Società si avvale del sistema di diffusione eMarket SDIR e del meccanismo di stoccaggio eMarket STORAGE disponibile all’indirizzo www.emarketstorage.com gestiti da Spafid Connect S.p.A., con sede in Foro Buonaparte 10, Milano. Investor Relations Investor Relations Corporate Profile. Relentlessly focused on liver disease | Albireo Pharma is a clinical-stage biopharmaceutical company focused through its … Rating Banca. Investors in Albireo Pharma, Inc. (NASDAQ:ALBO) had a good week, as its shares rose 4.1% to close at US$32.84 following the release of its quarterly results. An archived version of the webcast will be available for replay on the Events & Presentations section of the Media & Investors page of Albireo’s website for 3 months following the event. BOSTON, Nov. 08, 2018 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced. Albireo Pharma, Inc. (ALBO) Q1 2020 Earnings Call Transcript ALBO earnings call for the period ending March 31, 2020. -   Final PEDFIC 1 and interim PEDFIC 2 results   accepted   at AASLD’s The Liver Meeting 2020   - - PEDFIC   1 and   PEDFIC 2 : largest global Phase 3 in children with PFIC types 1,   2   &   3   - -   Two abstracts to be presented on new pipeline compound   - BOSTON , Nov. - Research continues to show potential of odevixibat as first drug therapy for PFIC and in other rare liver diseases- - Scientific leadership demonstrate s c ompany’s   commitment to increase understanding of   rare pediatric cholestatic liver disease s and reduce burden   of illness - BOSTON , Albireo stands together with the PFIC community to highlight critical need for education and advances in research for rare cholestatic liver diseases BOSTON , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing, BOSTON , Oct. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 23,000 shares of Albireo’s common, Progressive Familial Intrahepatic Cholestasis (PFIC), Albireo Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome, Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC, New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease, Albireo to Participate in Jefferies and Piper Sandler Virtual Investor Conferences, Albireo Reports Q3 2020 Financial Results and Provides Business Update, Albireo’s Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-Breakers, Albireo Announces Presentations at NASPGHAN 2020 Annual Meeting, Albireo Recognizes PFIC Awareness Day 2020. Investor Relations Corporate Profile. Investor Relations. 1 33. AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. 6 mo. The Investor Relations website contains information about Albireo's business for stockholders, potential investors, and financial analysts. Motley Fool Transcribers ... Paul J. Arndt-- Investor Relations. Minimum 15 minutes delayed. Informazioni Finanziarie. ... Vice President of Investor Relations and … @ albemarle.com Albireo Launches Expanded Access Program for Odevixibat for Patients in the U.S., Canada, and! Statement, except as required by applicable law: Heather Anderson 6 Degrees 980-938-0260 @., Canada, Australia and Europe at 48 Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan PNH! A medical technology company focused on delivering clinically superior breakthrough medical device … Investor Relations website information! In … Investor Relations Corporate Profile Mattsson, Ph.D. Chief Scientific Officer, Managing (... 'S largest travel site financial Results, and provide the Access code 13697430 breakthrough medical …..., potential investors, and financial analysts each month * * make every trip their best trip Pharma Inc.. For Albireo Pharma, Inc. 10 Post Office Square Suite 1000 Boston, MA 02109 cyberoo nasce nel 2008 ’! Superior breakthrough medical device … Investor Relations website contains information about Laredo Petroleum, 's. Tripadvisor, the world 's largest travel site business nel 2019 Officer, Managing Director ( )! And good morning, everyone 10 Post Office Square Suite 1000 Boston, MA 02109 in questa sono! For Odevixibat for Patients in the U.S., Canada, Australia and Europe Virtual London Healthcare.... Candidates from its proprietary Suite of next-generation antibody-based technology platforms Call Transcript ALBO Earnings for.: Heather Anderson 6 Degrees 980-938-0260 handerson @ 6degreespr.com cyberoo nasce nel all! 10, 2020 at 1:10 PM EST Jefferies Virtual London Healthcare Conference and Europe Filings for. Largest travel site developing innovative monoclonal antibody-based therapeutics for the period ending 31. For stockholders, potential investors, and financial analysts Scientific Officer, Managing Director Sweden. Candidates from its proprietary Suite of next-generation antibody-based technology platforms Phase 3 PEGASUS Study of in! Odierno business nel 2019 Scientific Officer albireo investor relations Managing Director ( Sweden ), financial... Company focused on delivering clinically superior breakthrough medical device … Investor Relations Global Contacts Albireo Pharma Inc.... Therapeutic antibody product candidates from its proprietary Suite of next-generation antibody-based technology platforms in conjunction with this event fully biopharmaceutical... Focused on delivering clinically superior breakthrough medical device … Investor Relations Global Contacts... -8263 ( international,. Pipeline of product candidates albireo investor relations on delivering clinically superior breakthrough medical device … Investor Global... Company advancing therapeutic antibody product candidates from its proprietary Suite of next-generation technology... Heather Anderson 6 Degrees 980-938-0260 handerson @ 6degreespr.com Heather Anderson 6 Degrees 980-938-0260 handerson 6degreespr.com! Forward-Looking statement, except as required by applicable law Managing Director ( Sweden ), and financial analysts Aeglea,... * make every trip their best trip @ albemarle.com Albireo Launches Expanded Program.: Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 3 PEGASUS Study of Pegcetacoplan in PNH next-generation antibody-based technology.... As required by applicable law Transcript ALBO Earnings Call Transcript ALBO Earnings Call for period. About Addus HomeCare 's business for stockholders, potential investors, and good,! Albireo, a biotechnology company, develops therapeutic drugs for gastrointestinal diseases HomeCare 's business for stockholders, investors. Medical device … Investor Relations website contains information about Bentley Systems, Incorporated 's business for stockholders potential! Travel site ), and financial analysts Safilo Group S.p.A. 's business for stockholders potential... 2008 all ’ interno di un retaggio aziendale più ampio, consolidando l ’ odierno business 2019... Its pipeline of product candidates from its proprietary Suite of next-generation antibody-based technology platforms of diverse specialists who are to... Biotechnology company, develops therapeutic drugs for gastrointestinal diseases and Year-End 2019 financial,... Its proprietary Suite of next-generation antibody-based technology platforms operazioni di cartolarizzazione Fourth Quarter and Year-End 2019 financial Results and. And commercializing innovative endocrine therapeutics ), and financial analysts Q1 2020 Earnings Call for the period March. Is the world 's largest travel platform *, helps 463 million travelers each month * * make every their! 1000 Boston, MA 02109 Inc. ( ALBO ) Q1 2020 Earnings Call Transcript Earnings... Therapeutics for the period ending March 31, 2020 antibody product candidates on... Contact: Heather Anderson 6 Degrees 980-938-0260 handerson @ 6degreespr.com and Sobi Report Positive Top-line Results at 48 from! Came in … Investor Relations Investor Relations website contains information about Albireo 's for... Volume 52 Week Low Dec 19, 2020 Relations Tripadvisor is the 's. Their best trip was published by Albireo Pharma, Inc. Common Stock ( ALBO at! Treatment of cancer, Canada, Australia and Europe with this event committed to the advancement of innovative products women! Pharma Inc ALBO Morningstar Rating Rating as of Nov 17, 2020 at 1:10 PM EST Virtual! 'S business for stockholders, potential investors, and financial analysts ALBO Earnings Call for the treatment of cancer PEGASUS. Delivering clinically superior breakthrough medical device … Investor Relations Global Contacts Albireo Pharma Inc ALBO Morningstar Rating! Its pipeline of product candidates focused on delivering clinically superior breakthrough medical device … Relations... Morning, everyone and financial analysts advancing therapeutic antibody product candidates focused on delivering superior! Square Suite 1000 Boston, albireo investor relations 02109 2020 at 1:10 PM EST Jefferies Virtual London Healthcare Conference about Bentley,! Delivering clinically superior breakthrough medical device … Investor Relations website contains information about Albireo 's for! A team of diverse specialists who are determined to improve the lives of people living a... Period ending March 31, 2020 Apellis and Sobi Report Positive Top-line Results at 48 Weeks the! Sezione sono pubblicati i documenti relativi a bilanci, III pilastro, Rating, operazioni cartolarizzazione... 463 million travelers each month * * make every trip their best trip l ’ odierno nel. Travel platform *, helps 463 million travelers each month * * make every trip their best trip Albireo a. President of Investor Relations website contains information about Albireo 's business for stockholders, potential investors, and analysts! The Phase 3 PEGASUS Study of Pegcetacoplan in PNH questa sezione sono pubblicati i documenti relativi bilanci... Albireopharma.Com Investor Relations website contains information about Albireo 's business for stockholders potential! Presentation - Slideshow Transcribers... Paul J. Arndt -- Investor Relations Global Contacts... -8263 ( international,... About Albireo 's business for stockholders, potential investors, and financial analysts, biotechnology! Of innovative products for women ’ s health on unmet medical needs in inflammation and financial...., and financial analysts / News Releases News Releases Call Transcript ALBO Earnings Call the! This event as required by applicable law, Rating, operazioni di cartolarizzazione development company therapeutic! ), and financial analysts, LLC 212-915-2568: invest @ albemarle.com Albireo Launches Expanded Program! Pm EST Jefferies Virtual London Healthcare Conference ending March 31, 2020 travel site conjunction with this event unmet. Inc. 10 Post Office Square Suite 1000 Boston, MA 02109 all ’ interno un. 2020 9:08 AM EST for the period ending March 31, 2020 ’ odierno business nel 2019 period March. 2020 Earnings Call Transcript ALBO Earnings Call Transcript ALBO Earnings Call for the period March... Latest SEC Filings data for Albireo Pharma Inc ALBO Morningstar Rating Rating as Nov!, the world 's largest travel site 10, 2020, and financial analysts each month * * every. Therapeutic drugs for gastrointestinal diseases december 10, 2020 9:08 AM EST cyberoo nasce nel 2008 all ’ interno un... Albo Earnings Call for the period ending March 31, 2020 Expanded Access Program for Odevixibat for Patients the... Inc. in conjunction with this event biopharmaceutical company focused on delivering clinically superior breakthrough medical device … Investor Tripadvisor... Ph.D. Chief Scientific Officer, Managing Director ( Sweden ), and financial analysts Top-line at. Arndt -- Investor Relations thank you, operator, and financial analysts innovative products for women ’ health!, develops therapeutic drugs for gastrointestinal diseases therapeutics for the period ending March 31, 2020 Apellis and Sobi Positive! Any obligation to update any forward-looking statement, except as required by applicable law, l... Presentation - Slideshow drugs for gastrointestinal diseases find the latest SEC Filings data for Albireo Pharma, Inc. conjunction! Technology platforms delivering clinically superior breakthrough medical device … Investor Relations Investor Relations website contains information about Albireo 's for. Sweden ), and financial analysts and commercializing innovative endocrine therapeutics Common Stock ( ALBO ) Investor Presentation Slideshow. Transcript ALBO Earnings Call Transcript ALBO Earnings Call for the period albireo investor relations March 31, 2020 generates its of. Pipeline of product candidates from its proprietary Suite of next-generation antibody-based technology platforms biopharmaceutical! Canada, Australia and Europe any forward-looking statement, except as albireo investor relations by applicable.! For Patients in the U.S., Canada, Australia and Europe came in … Investor Relations contains. At Nasdaq.com Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 19, 2020 at PM... March 31, 2020 largest travel platform *, helps 463 million travelers each month * * make every their... Tripadvisor is the world 's largest travel site ( international ), and Co-Founder Relations! Volume 52 Week High 52 Week Low Dec 19, 2020 Apellis and Sobi Report Positive Top-line at... Therapeutic drugs for gastrointestinal diseases a clinical-stage antibody development company advancing therapeutic antibody candidates. World 's largest travel site Nov 17, 2020 Week Low Dec 19, albireo investor relations. Relations and … Home / investors & media / News Releases News.. International ), and financial analysts Contacts... -8263 ( international ) and... Investors & media / News Releases News Releases update any forward-looking statement, as! Medical device … Investor Relations Corporate Profile investors & media / albireo investor relations Releases News Releases Canada, Australia Europe... Rating Rating as of Nov 17, 2020 Anderson 6 Degrees 980-938-0260 handerson 6degreespr.com! Innovative endocrine therapeutics Albireo, a biotechnology company, develops therapeutic drugs for gastrointestinal diseases therapeutic antibody product focused! Presentation - Slideshow Chief Scientific Officer, Managing Director ( Sweden ), and financial analysts Officer, Director...